Penta HIV Trials

Adeqaute dolutegravir exposure dosed BID with rifampicin in children 6 to < 18 years

13 Mar, 2020

Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E,Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and the…
Read More

Analysing small groups within clinical trials, while borrowing information from larger groups

14 Nov, 2019

Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A,  White I, and ODYSSEY trial team Published in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019
Read More

Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to <20kg dosed using WHO weight bands

14 Sep, 2019

Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail Team Published in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019
Read More

Adult dolutegravir 50mg film-coated tablets in children living with HIV weighing 20 to <25 kg

14 Apr, 2019

Authors: Bollen P, Turkova A, Mujuru H, et al. for the ODYSSEY Trial Team Published in: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_830
Read More

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries

26 Dec, 2018

Authors: Tierrablanca LE, Ochalek J, Ford D, et al; for BREATHER (PENTA 16) Trial Group Published in: Medicine (Baltimore). 2018;97(5):e9698 Objectives To analyze the cost effectiveness of short-cycle therapy (SCT), where patients take…
Read More

Weekends-off efavirenz -based antiretroviral therapy in HIV infected children, adolescents and young adults (BREATHER): extended follow-up results of a randomised, open-label, non-inferiority trial

26 Dec, 2018

Authors: Turkova A, Moore CL, Butler K, et al. for BREATHER (PENTA 16) Trial Group. Published in: PLos One. 2018;13(4):e0196239. Background Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing…
Read More

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing 14 to <25kg on film-coated dolutegravir 25mg tablets

14 Oct, 2018

Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22
Read More

ODYSSEY: design, current status, and baseline characteristics

14 Oct, 2018

Authors: Moore CL,  Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34
Read More

“I failed to take them as I should and now I’m scared”: how can we support adolescents’ adherence on second line HIV treatment

09 Oct, 2018

Authors: Bernays S, Namukwaya S, Mupambireyi Z, Nanduudu A, Mujuru H, Turkova A, Gibb DM, Seeley J, and the ODYSSEY Trial Team. Published in: 10th International Workshop on HIV Pediatrics,…
Read More

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing ≥25kg after switching to 50mg film-coated dolutegravir tablets in the ODYSSEY trial

14 Sep, 2018

Authors: Turkova A, Bollen P, Kaudha E, et al. The ODYSSEY Trial Team Published in: Oral Presentation at 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018
Read More

Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?

21 Dec, 2017

Authors: Bernays S, Paparini S, Seeley J, Namukwaya Kihika S, Gibb D, Rhodes T. Published in: BMJ Open. 2017;7(2):e012934 Objectives A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which…
Read More

“How Do We Start? And How Will They React?” Disclosing to Young People with Perinatally Acquired HIV in Uganda

13 Dec, 2017

Despite great advances in pediatric HIV care, rates and the extent of full disclosure of HIV status to infected children remain low especially in resource-constrained setting. The World Health Organisation…
Read More

“Not Taking it Will Just be Like a Sin”: Young People Living with HIV and the Stigmatization of Less-Than-Perfect Adherence to Antiretroviral Therapy

01 Jul, 2017

Global health priorities are being set to address questions on adherence to HIV antiretroviral therapy in adolescence. Few studies have explored young people's perspectives on the complex host of social…
Read More

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

01 Jun, 2016

Author: Butler K, Inshaw J, Ford D, et al. Published in:  Health Technol Assess. 2016;20(49):1-108. Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents…
Read More

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

01 Jun, 2016

Author: The BREATHER (PENTA 16) Trial Group Published in: Lancet HIV. 2016;3(9):e421-430 Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends,…
Read More

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption

24 Apr, 2016

Authors: Ananworanich J, Melvin D, Ramos Amador JT, et al; on behalf of the PENTA 11 study group. Published in: AIDS. 2016;30(7):1075-81. Objective Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of…
Read More

When information does not suffice: young people living with HIV and communication about ART adherence in the clinic

01 Jan, 2016

Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68 Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young…
Read More

HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds

18 Sep, 2015

Authors: Harrison L, Melvin A, Fiscus S, et al. For PENPACT-1 (PENTA 9PACTG 390) Study Team. Published in: JAIDS 2015;70(1):42-53 Background The PENPACT-1 trial compared virologic thresholds to determine when to switch…
Read More
1 2 3 4 5 8